Next-generation AAV gene therapy from joined German forces
The viral vector specialist SIRION Biotech GmbH today announces the signing of a preferred partnership agreement with He…
The viral vector specialist SIRION Biotech GmbH today announces the signing of a preferred partnership agreement with He…
SIRION Biotech GmbH and Vibalogics GmbH, have signed a strategic partnership agreement designed to meet demand from gene…
SIRION Biotech GmbH, a world leader in viral vector-based gene delivery technologies for gene & cell therapy, announced…
With the beginning of a new fiscal year SIRION Biotech GmbH, located at the Innovation and Start-Up Center for Biotechno…
Die im Innovations- und Gründerzentrum für Biotechnologie (IZB) Martinsried ansässige SIRION Biotech GmbH meldet zu Jahr…
SIRION Biotech has taken a critical step in the company's development towards a viral vector Center of Competence: all t…
SIRION Biotech entwickelt sich weiter in Richtung Kompetenzzentrum für virale Vektoren: alle 3 wichtigen Typen viraler V…
Adenovirus vector cloning and production still remain tricky with rather low yields and limited success. The brand new A…
SIRION Biotech announced today its novel lentivirus portfolio for the most sophisticated in vitro applications. Besides…